drugset / Trial / NCT05508334

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

NCT05508334

Phase 1/2 Completed 41 enrolled RemeGen Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to allow RC88 treatment of patients with advanced solid tumours to assess the safety and tolerability of clinical pharmacology studies

Timeline

Start
2023-01-30
Primary completion
2025-11-26
Completion
2025-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject RC88 Unknown Intravenous

Indications